Research Article
Serum Legumain Is Associated with Peripheral Artery Disease in Patients with Type 2 Diabetes

Wen Wei,1,2 Shujin Chen,3 Jianqing Huang,1 Yan Tong,1 Jushun Zhang,1 Xiuping Qiu,1 Wenrui Zhang,4 Hangju Chen,1 Rong Huang,1 Jin Cai,5 and Mei Tu1

1Department of Endocrinology, Fujian Longyan First Hospital, Longyan First Affiliated Hospital of Fujian Medical University, Longyan 364000, China
2The Second School of Clinical Medicine, Southern Medical University, Guangzhou 510515, China
3Department of Ultrasonography, Fujian Longyan First Hospital, Longyan First Affiliated Hospital of Fujian Medical University, Longyan 364000, China
4Department of Neurosurgery, Ren Ji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 200240, China
5Department of Endocrinology, Fujian Longyan First Hospital, Fujian Medical University, Fuzhou 350004, China

Correspondence should be addressed to Mei Tu; lysytm@qq.com

Received 6 August 2021; Revised 27 October 2021; Accepted 16 November 2021; Published 18 December 2021

Academic Editor: Ryan T. Crews

Copyright © 2021 Wen Wei et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Legumain is related to carotid atherosclerotic plaques and may be a new biomarker of carotid atherosclerosis. However, the association between legumain and peripheral artery disease (PAD) of lower extremity has been less studied. This study is aimed at exploring the potential link between legumain and PAD in patients with type 2 diabetes mellitus (T2DM). Methods. A cross-sectional study was conducted on 483 hospitalized T2DM patients. The serum legumain level was measured by a sandwich enzyme-linked immunosorbent assay. PAD was evaluated by color Doppler sonography. The association between legumain and PAD was tested by logistic regression. The predictive power of legumain for PAD was evaluated with the receiver-operating-characteristic (ROC) curve. Results. Overall, 201 (41.6%) patients suffered from PAD. Patients with PAD had significantly higher serum legumain level than those without PAD [11.9 (6.3, 17.9) μg/L vs. 7.6 (3.2, 14.2) μg/L, p < 0.001]. Logistic regression showed that a higher serum legumain level was independently associated with a greater risk of PAD in T2DM patients [adjusted odds ratio (aOR): 1.03; 95% confidence interval (CI): 1.01-1.06]. The area under the ROC curve was 0.634 (95% CI, 0.585 to 0.684). Conclusion. Higher serum legumain level was significantly correlated with an increased risk of PAD in T2DM patients.

1. Introduction

Peripheral artery disease (PAD) of the lower extremity is one of the common macrovascular complications of diabetes and is associated with a substantial increase in the risk of foot ulceration and amputation [1, 2]. Furthermore, PAD is an independent predictor of cardiovascular and cerebrovascular ischemic events, the leading causes of mortality and morbidity in diabetic patients [3]. Early detection and treatment of PAD are critical to prevent amputation and mortality of the diabetic population.

Legumain, also known as asparaginyl endopeptidase (AEP), belongs to the C13 family of cysteine proteases that include caspases and separases [4]. Legumain has been found to play a role in antigen presentation [5], invasion/metastasis of tumor [6, 7], and neurodegenerative diseases [8–10]. Recent studies indicate that legumain is upregulated in carotid atherosclerotic plaques and might be a new and early biomarker of carotid atherosclerosis [11–13]. However, no study has evaluated the serum legumain level in patients with PAD of the lower extremity.

Therefore, in this study, we aim to evaluate the association between serum legumain and PAD and whether serum legumain could be used as a predictor of PAD in patients with type 2 diabetes mellitus (T2DM).
2. Methods

2.1. Study Population and Data Sources. The cross-sectional study included adult patients (≥18 years of age) with T2DM who were hospitalized at Longyan First Affiliated Hospital of Fujian Medical University, Fujian, China, between July 2018 and June 2019. T2DM was diagnosed according to the World Health Organization (WHO) criteria. Patients with other types of diabetes and pregnant women were excluded. We also excluded patients with ketoacidosis, hyperosmolar status, acute severe infection, chronic or acute renal diseases on hemodialysis, autoimmune disease, malignant cancer, and severe cardiac insufficiency. Eventually, 483 patients were included. The study was approved by the institutional Ethics Research Committee of Longyan First Affiliated Hospital of Fujian Medical University. All patients gave written informed consent for participation in the study.

Data were extracted from the electronic clinical management records system of Longyan First Affiliated Hospital of Fujian Medical University. Information mainly included demographic characteristics, medical history, medications, laboratory test results, and other clinical variables. Height, weight, waist circumference (WC), and blood pressure (BP) were assessed on a standardized form by the nurse on admission. Venous blood samples were collected in the early morning after overnight fasting.

Body mass index (BMI) was calculated as weight/height² (kg/m²). Homeostatic model assessment-insulin resistance (HOMA-IR) was calculated using the following formula: fasting blood glucose (mmol/L) \times fasting plasma insulin (mU/L)/22.5. Estimated glomerular filtration rate (eGFR) value was calculated based on serum creatinine (Scr) level using the Modification of Diet in Renal Disease (MDRD) formula.

2.2. Ultrasonography Measurements. We followed the methods of He et al. [14]. Color Doppler sonography was carried out with a Philips Ultrasound (Epiq5, Bothell, WA) equipped with a 5-12 MHz linear array transducer. The ultrasonography was conducted by two experienced ultrasonographers according to a standardized technique. After the participants had kept in the supine position for 5 min, the transducer was placed on the lower limbs to show both vessel imaging and blood flow characteristics. Lower extremity arteries were evaluated bilaterally at the levels of the seven locations: common femoral artery, profunda femoris artery, superficial femoral artery, popliteal artery, anterior tibial artery, posterior tibial artery, and peroneal artery. At each location, intima-media thickness (IMT) and atherosclerotic plaques were recorded. The IMT on both sides was measured as the distance between the leading edge of the lumen-intima echo and the leading edge of the media-adventitia echo [15].

Artery intimal thickening was defined as a focal thickening from the intima-lumen interface to the media-adventitia interface of over 1.5 mm [16]. PAD was defined as the presence of arterial atherosclerotic plaques in any of the aforementioned arterial segments [17, 18].

2.3. Measurement of Legumain. After a fast for 8 hours, approximately 2-3 mL of peripheral blood was obtained using a collection tube without additives from each subject within 24 hours after admission. Serum legumain (µg/L) concentration was measured using a commercially available enzyme-linked immunosorbent assay (jianglai Biotechnology Co., Ltd., Shanghai, China) according to the manufacturer's instructions.

2.4. Bias Control. A number of measures were taken to mitigate bias, such as strict inclusion and exclusion criteria, standardized measurement procedures for anthropometric indexes and blood indicators, measurement of arterial plaque according to a standardized technique by two experienced ultrasonographers, and a multivariable regression model to correct confounding factors in statistical analysis.

2.5. Sample Size Consideration. To obtain unbiased estimates of the regression coefficients, it has previously been suggested to include 10-20 events per degree of freedom in the predictors of logistic regression analysis. The study consisted of 483 patients, 201 (41.6%) of whom had PAD. Thus, the event per variable (EPV) value was 10-20 for the regression model.

2.6. Statistical Analyses. Continuous variables were expressed as mean ± standard deviation or median (quartile range), and categorical variables were expressed as frequency counts and percentages. Baseline characteristics stratified by whether or not PAD were compared using the two-sample independent t-test or the Mann-Whitney U nonparametric test for continuous variables and the chi-square test for categorical variables. The trend of PAD prevalence with serum legumain level changes (cut-off by quartile range) was assessed using the Cochran-Armitage test.

The correlation between PAD and legumain was tested by univariable and multivariable logistic regression analyses. Variables that were entered into the multivariable model were carefully selected based on variables associated with known risk factors or variables with p value < 0.05 in baseline or in univariable regression analysis. The predictive power of legumain for PAD was evaluated with the receiver-operating-characteristic (ROC) curve using DeLong's method and expressed by the C-statistic.

Considering that legumain is upregulated in carotid atherosclerotic plaques and that most PAD patients likely have concomitant carotid plaques, we performed sensitivity analysis in T2DM patients without carotid plaque. There was a very small amount of missing data for variables of interest, so we did not deal with missing values (Supplementary Table 3).

All analyses were performed with R software (version 4.0.5; R Foundation for Statistical Computing, Vienna, Austria). A two-sided p value < 0.05 indicated significance for all analyses.
## Table 1: Comparison of clinical characteristics between patients with and without PAD.

| Characteristic                          | With PAD (n = 201) | Without PAD (n = 282) | p value  |
|-----------------------------------------|--------------------|-----------------------|----------|
| **Demographic characteristics**         |                    |                       |          |
| Age (years)                             | 62 ± 10            | 54 ± 10               | <0.001   |
| Male, n (%)                             | 130 (64.7)         | 154 (54.6)            | 0.034    |
| WC (cm)                                 | 90.1 ± 9.0         | 89.1 ± 10.3           | 0.335    |
| BMI (kg/m²)                             | 24.0 ± 2.8         | 24.5 ± 3.7            | 0.111    |
| **Medical history and clinical condition** |                  |                       |          |
| Smoking history, n (%)                  | 88 (43.8)          | 81 (28.7)             | 0.001    |
| Hypertension, n (%)                     | 103 (51.2)         | 97 (34.4)             | <0.001   |
| SBP (mmHg)                              | 140 ± 19.2         | 134.6 ± 18.3          | <0.001   |
| **Laboratory examination**              |                    |                       |          |
| Legumain (μg/L)                         | 11.9 (6.3, 17.9)   | 7.6 (3.2, 14.2)       | <0.001   |
| FBG (mmol/L)                            | 9.2 ± 3.4          | 8.8 ± 3.4             | 0.242    |
| 2hPBG (mmol/L)                          | 13.0 ± 4.8         | 13.0 ± 4.9            | 0.965    |
| HbA1C (%)                               | 10.4 ± 2.4         | 10.4 ± 2.7            | 0.945    |
| HOMA-IR                                 | 17.3 (8.1, 31.9)   | 12.9 (7.2, 26.1)      | 0.037    |
| TG (mmol/L)                             | 2.1 ± 1.7          | 2.0 ± 1.6             | 0.513    |
| TC (mmol/L)                             | 4.9 ± 1.3          | 4.9 ± 1.2             | 0.831    |
| HDL-C (mmol/L)                          | 1.3 ± 0.6          | 1.3 ± 0.4             | 0.357    |
| LDL-C (mmol/L)                          | 3.1 ± 1.1          | 3.2 ± 1.0             | 0.748    |
| eGFR (mL/min/1.73mm²)                   | 107.6 ± 37.7       | 118.5 ± 37.3          | 0.003    |
| UA (μmol/L)                             | 350.9 ± 95.0       | 341.3 ± 89.3          | 0.292    |
| hs-CRP (mg/L)                           | 1.4 (0.7, 3.0)     | 1.2 (0.6, 2.2)        | 0.091    |
| HCY (μmol/L)                            | 11.5 ± 3.1         | 10.6 ± 3.5            | 0.006    |
| **Administered drugs**                  |                    |                       |          |
| Insulin, n (%)                          | 46 (22.9)          | 47 (16.7)             | 0.111    |
| OADs, n (%)                             | 129 (64.5)         | 160 (57.3)            | 0.138    |
| Statins, n (%)                          | 18 (9.0)           | 6 (2.1)               | 0.001    |
| Aspirin, n (%)                          | 17 (8.5)           | 7 (2.5)               | 0.006    |
| ACEI/ARB, n (%)                         | 36 (18.0)          | 27 (9.7)              | 0.012    |
| CCB, n (%)                              | 42 (21.0)          | 33 (11.8)             | 0.009    |
| β-Blockers, n (%)                       | 15 (7.5)           | 8 (2.9)               | 0.034    |
| Diuretic, n (%)                         | 6 (3.0)            | 5 (1.8)               | 0.575    |

Abbreviation: PAD: peripheral artery disease; WC: waist circumference; BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; DR: diabetic retinopathy; DPN: diabetic peripheral neuropathy; DN: diabetic nephropathy; NAFLD: nonalcoholic fatty liver disease; FBG: fasting blood glucose; 2hPBG: 2 hours postprandial blood glucose; HbA1c: glycosylated hemoglobin; HOMA-IR: homeostatic model assessment-insulin resistance; TG: triglyceride; TC: total cholesterol; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; eGFR: estimated glomerular filtration rate; UA: uric acid; hs-CRP: hypersensitive C-reactive protein; HCY: homocysteine; OADs: oral antidiabetic drugs; ACEI/ARB: angiotensin-converting enzyme inhibitor/angiotensin receptor blocker; CCB: calcium channel blocker.
3. Results

3.1. Clinical Characteristics. A total of 483 T2DM patients with the mean age of 58 ± 11 years, including 284 men and 199 women, were included in this study. The prevalence of PAD was 41.6%. The patients were divided into two groups based on the presence of PAD. The clinical characteristics of the subjects are summarized in Table 1.

Compared with patients without PAD, patients with PAD were likely to be older (62 ± 10 years vs. 54 ± 10 years, p < 0.001) and be male (64.7% vs. 54.6%, p = 0.034). These patients demonstrated a higher legumain level [11.9 (6.3, 17.9) μg/L vs. 7.6 (3.2, 14.2) μg/L, p < 0.001], homocysteine (Hcy) level (11.5 ± 3.1 vs. 10.6 ± 3.5 μmol/L, p = 0.006), and HOMA-IR value [17.3 (8.1, 31.9) vs. 12.9 (7.2, 26.1), p = 0.037]. They also had longer duration of diabetes [8 (3, 11) years vs. 5 (1, 10) years, p < 0.001], accompanied with higher rates of diabetic complications such as diabetic retinopathy (DR) (29.4% vs. 16.3%, p = 0.009), diabetic peripheral neuropathy (DPN) (67.2% vs. 51.6%, p = 0.023), and diabetic nephropathy (DN) (26.6% vs. 10.4%, p < 0.001) (Table 1).

The incidences of smoking, hypertension, coronary artery disease (CAD), and stroke in patients with PAD were higher than those in patients without (43.8% vs. 28.7%, p = 0.001; 51.2% vs. 34.4%, p < 0.001; 13.9% vs. 2.5%, p < 0.001; 7.0% vs. 1.4%, p = 0.003, respectively). Medication use is also shown in Table 1.

3.2. Association between Serum Legumain Level and PAD. The median (25th and 75th percentiles) serum legumain level among the entire study population was 9.1 (4.4-15.7) μg/L. The prevalence of PAD showed an increasing trend in higher serum legumain levels (Figure 1).

Multivariable logistic regression showed that the higher serum legumain level was independently associated with a greater risk of PAD in T2DM patients (adjusted odds ratio [aOR]: 1.03; 95% confidence interval [CI]: 1.01-1.06). The covariates included in the multivariable analysis were age, gender, duration of diabetes, hypertension, low-density lipoprotein cholesterol (LDL-C), hypersensitive C-reactive protein (hs-CRP), HCY, HOMA-IR, eGFR, smoke, DR, and carotid atherosclerotic plaque (Table 2).

The results demonstrated that patients with PAD showed a higher serum legumain level than those without, and the prevalence of PAD increased with the increase of the serum legumain level. A high legumain level was independently associated with a greater risk of PAD.

PAD is one of the common macrovascular complications of diabetes. Diabetes was significantly related with the presence of atherosclerotic plaques in the lower extremity [19]. The prevalence of atherosclerotic plaques in femoral arteries was 77% in elderly Finns with diabetes or impaired glucose tolerance [20]. The prevalence of lower extremity artery plaques in our study was 41.6%, but the patients in our study were younger with the mean age of 58 years. Diabetes-associated PAD is often associated with diabetic peripheral neuropathy [21]. Decreased pain and body temperature caused by neuropathy may mask the symptoms of PAD (such as resting pain), leading to delayed diagnosis of PAD and more serious consequences such as gangrene and amputations [22, 23]. Due to the similar pathophysiological mechanisms (such as oxidative stress and endothelial dysfunction) of PAD and atherosclerosis in other vessels, PAD is closely related to the occurrence of cardiovascular disease [1, 2, 24]. Given the heavy public health burden, economic burden, and poor prognosis caused by diabetes-related amputations [25], early identification of effective biomarkers for PAD is essential. Our study showed that the high serum legumain level significantly correlated with an increased risk of PAD in T2DM patients. Measurement of the serum legumain level may allow clinicians to identify diabetic patients at elevated risk for PAD. However, the predictive value of the serum legumain for PAD needs to be confirmed in further larger prospective studies.

It is known that atherosclerosis is characterized by a complex process of vascular injury; inflammation, with monocyte adhesion to endothelial cells (ECs); lipid deposition within macrophage foam cells; neointimal hyperplasia, involving vascular smooth muscle cells (VSMCs); and

Figure 1: Prevalence of PAD stratified by quartiles of serum legumain level.
extracellular matrix (ECM) remodeling [26, 27]. The mechanism underlying the relationship between legumain and arterial atherosclerotic plaque may be as follows. Clerin et al. indicated that the increased legumain level correlated with increased accumulation of inflammatory cells in early-to-late-stage atherosclerotic lesions in both human coronary arteries and mouse aortas. Legumain gene expression could be regulated by proinflammatory cytokines such as interleukin-1β (IL-1β), interferon-γ (IFN-γ), or tumor necrosis factor-α (TNF-α) [28]. Legumain promoted atherosclerotic vascular remodeling by enhancing macrophage foam cell formation; VSMC migration; and collagen-3, fibronectin, and elastin production by VSMCs [29]. Papaspyridonos et al. demonstrated that legumain was coexpressed with matrix metalloproteinases (MMPs), so it was regarded as a contributor to plaque rupture [30]. Legumain has also been reported to facilitate atherosclerotic plaque formation and plaque rupture via enhanced ECM degradation [11].

Consistent with previous studies, we found that some of the traditional risk factors for atherosclerosis were also present in this population. As expected, age, smoking, hypertension, duration of diabetes, and insulin resistance were independently associated with the presence of PAD in the T2DM patients. Therefore, smoking cessation and treatment of hypertension and insulin resistance are important in order to prevent atherosclerosis in the lower extremity arteries in diabetic patients. The association between legumain and inflammation has been indicated elsewhere [12, 31]. Chronic inflammation has been established as a major mechanism to cause insulin resistance and atherosclerosis [32]. Therefore, the serum legumain level may reflect the systemic inflammation in patients with atherosclerosis. Serum legumain associated with atherosclerosis and inflammation may improve risk stratification in T2DM patients. On the other hand, the benefit of targeting legumain in atherosclerosis therapy may be its effect on inflammation.

### Table 2: Logistic regression analysis for PAD.

|                      | Univariable | Multivariable |
|----------------------|-------------|---------------|
|                      | OR (95% CI) | p value      | aOR (95% CI) | p value      |
| Legumain             | 1.02 (1.01-1.03) | 0.001 | 1.03 (1.01-1.06) | 0.006 |
| Age                  | 1.08 (1.06-1.10) | <0.001 | 1.12 (1.07-1.17) | <0.001 |
| Male                 | 1.52 (1.05-2.21) | 0.027 | 1.74 (0.71-4.29) | 0.224 |
| Duration of diabetes | 1.08 (1.04-1.11) | <0.001 | 1.09 (1.02-1.16) | 0.007 |
| Hypertension         | 2.01 (1.39-2.91) | <0.001 | 2.77 (1.40-5.60) | 0.004 |
| LDL-C                | 0.97 (0.81-1.17) | 0.748 | 1.21 (0.86-1.73) | 0.275 |
| hs-CRP               | 1.06 (1.02-1.12) | 0.009 | 0.96 (0.86-1.07) | 0.484 |
| HCY                  | 1.08 (1.02-1.14) | 0.007 | 0.95 (0.85-1.06) | 0.352 |
| HOMA-IR              | 1.01 (1.00-1.02) | 0.005 | 1.02 (1.01-1.04) | 0.009 |
| eGFR                 | 0.99 (0.99-1.00) | 0.004 | 1.01 (1.00-1.02) | 0.208 |
| Smoking history      | 1.93 (1.32-2.83) | 0.001 | 3.53 (1.40-9.34) | 0.009 |
| DR                   | 1.84 (1.20-2.86) | 0.006 | 1.02 (0.51-2.01) | 0.954 |
| Carotid plaque       | 4.01 (2.69-6.06) | <0.001 | 1.29 (0.63-2.65) | 0.487 |
| BMI                  | 0.96 (0.90-1.01) | 0.113 |
| WC                   | 1.01 (0.99-1.03) | 0.334 |
| SBP                  | 1.02 (1.01-1.03) | 0.001 |
| DPN                  | 1.42 (0.96-2.10) | 0.082 |
| DN                   | 1.39 (0.98-1.97) | 0.063 |
| Stroke               | 5.20 (1.83-18.57) | 0.004 |
| FBG                  | 1.03 (0.98-1.09) | 0.242 |
| 2hPBG                | 1.00 (0.96-1.04) | 0.965 |
| HbA1C                | 1.00 (0.93-1.08) | 0.945 |
| TG                   | 1.04 (0.92-1.17) | 0.513 |
| TC                   | 0.98 (0.84-1.15) | 0.831 |
| HDL-C                | 1.21 (0.80-1.88) | 0.362 |
| UA                   | 1.00 (1.00-1.00) | 0.292 |
| Insulin              | 1.48 (0.94-2.34) | 0.089 |
| OADs                 | 1.35 (0.93-1.97) | 0.115 |
| Statins              | 4.53 (1.86-12.67) | 0.002 |
| Aspirin              | 3.63 (1.53-9.55) | 0.005 |

Abbreviation as in Table 1.
In diabetic patients, atherosclerotic lesions were more common in lower extremity arteries than carotid arteries. Schneider et al. found that PAD but not carotid and/or coronary artery diseases was a relevant risk factor for both minor and major amputation [33]. Furthermore, PAD was closely associated with the occurrence of cardiovascular disease. The latest researches demonstrated that legumain was associated with the presence of complex coronary lesions and the outcome in acute cardiovascular events [31, 34–36]. Therefore, a follow-up of the outcome in PAD subjects is necessary to elucidate whether serum legumain might be a clinically relevant vascular disease biomarker or a new strategy for PAD.

Our study has several limitations. First, the cross-sectional design limits our ability to assess the causal relationship between serum legumain and PAD, and the predictive value of serum legumain for PAD needs to be confirmed in further larger prospective studies that include a nondiabetic population. Second, the ankle-brachial index and symptoms of intermittent claudication or ischemic resting pains were not detected in this study. Third, the precise regulatory mechanism of legumain and atherosclerotic plaque needs further investigation. Finally, it was a cross-sectional single-center study with some inherent bias. However, efforts were made to mitigate bias.

5. Conclusion

In conclusion, the high serum legumain level was independently associated with an increased risk of PAD in Chinese patients with T2DM. Measurement of the serum legumain level may allow clinicians to identify diabetic patients at elevated risk for PAD. Further studies revealing the imminent connection of legumain with the pathology of diabetes-associated PAD may confirm the predictive value of serum legumain for PAD and provide a new strategy for PAD.

Data Availability

The data used to support the findings of this study have not been made available because of patient privacy.

Ethical Approval

The study was approved by the institutional Ethics Research Committee of Longyan First Affiliated Hospital of Fujian Medical University.

Conflicts of Interest

The authors declare that they have no competing interests.

Authors’ Contributions

Substantial contributions to the conception and design of the study were made by MT; data collection was handled by JQH, YT, JSZ, XPQ, HJC, RH, and JC; data analysis and/or interpretation of data for the work was made by WW, JQH, and JSZ; vascular assessment or serum legumain measurement was made by SJC and WRZ; drafting of the work or revising it critically for important intellectual content was made by WW; and all authors gave final approval of the version to be published.

Acknowledgments

We are very grateful to all the staff for helping with the present study. We are grateful to all participants for their dedication to data collection. This research was funded and supported by the Natural Science Foundation of the Fujian Provincial Science and Technology Department (2018J01409) and the Sailing Project of Fujian Medical University (2017XQ1183).

Supplementary Materials

The sensitivity analysis in T2DM patients without carotid plaque and the information of missing values of baseline variables in total patients were included in supplementary materials. (Supplementary Materials)

References

[1] C. B. Olivier, H. Mulder, W. R. Hiatt et al., “Incidence, characteristics, and outcomes of myocardial infarction in patients with peripheral artery disease: insights from the EUCLID trial,” JAMA Cardiology, vol. 4, no. 1, pp. 7–15, 2019.
[2] P. Pourghaderi, K. M. Yuquimpo, C. Roginski Guetter, L. Mansfield, and H. S. Park, “Outcomes following lower extremity amputation in patients with diabetes mellitus and peripheral arterial disease,” Annals of Vascular Surgery, vol. 63, pp. 259–268, 2020.
[3] S. M. Grundy, B. Howard, S. Smith Jr., R. Eckel, R. Redberg, and R. O. Bonow, “Prevention conference VI: diabetes and cardiovascular disease: executive summary: conference proceeding for healthcare professionals from a special writing group of the American Heart Association,” Circulation, vol. 105, no. 18, pp. 2231–2239, 2002.
[4] S. Ishii, “[42] Legumain: Asparaginyl endopeptidase,” Methods in Enzymology, vol. 244, pp. 604–615, 1994.

[5] B. Manoury, E. W. Hewitt, N. Morrice, P. M. Dando, A. J. Barrett, and C. Watts, “An asparaginyl endopeptidase processes a microbial antigen for class II MHC presentation,” Nature, vol. 396, no. 6712, pp. 695–699, 1998.

[6] C. W. Mai, F. F. Chung, and C. O. Leong, “Targeting legumain as a novel therapeutic strategy in cancers,” Current Drug Targets, vol. 18, no. 11, pp. 1259–1268, 2017.

[7] M. S. Toss, I. M. Miligy, K. L. Gorringe et al., “Legumain is an independent predictor for invasive recurrence in breast ductal carcinoma in situ,” Modern Pathology, vol. 32, no. 5, pp. 639–649, 2019.

[8] Z. Zhang, M. Song, X. Liu et al., “Cleavage of tau by asparaginyl endopeptidase mediates the neurofibrillary pathology in Alzheimer’s disease,” Nature Medicine, vol. 20, no. 11, pp. 1254–1262, 2014.

[9] H. Rosenmann, “Asparagine endopeptidase cleaves tau and promotes neurodegeneration,” Nature Medicine, vol. 20, no. 11, pp. 1236–1238, 2014.

[10] S. Ayyadevara, M. Balasubramaniam, Y. Gao, L. R. Yu, R. Alla, and R. Shmookler Reis, “Proteins in aggregates functionally impact multiple neurodegenerative disease models by forming proteasome-blocking complexes,” Aging Cell, vol. 14, no. 1, pp. 35–48, 2015.

[11] K. L. Mattock, P. J. Gough, J. Humphries et al., “Legumain and cathepsin-L expression in human unstable carotid plaque,” Atherosclerosis, vol. 208, no. 1, pp. 83–89, 2010.

[12] N. N. Lunde, S. Holm, T. B. Dahl et al., “Increased levels of legumain in plasma and plaques from patients with carotid atherosclerosis,” Atherosclerosis, vol. 257, pp. 216–223, 2017.

[13] M. Magnoni, E. Ammirati, and P. G. Camici, “Non-invasive molecular imaging of vulnerable atherosclerotic plaques,” Journal of Cardiology, vol. 65, no. 4, pp. 261–269, 2015.

[14] X. He, J. Su, X. Ma et al., “The association between serum growth differentiation factor 15 levels and lower extremity atherosclerotic disease is independent of body mass index in type 2 diabetes,” Cardiovascular Diabetology, vol. 19, no. 1, p. 40, 2020.

[15] X. Zhang, Y. Hu, H. Zeng et al., “Serum fibroblast growth factor 21 levels is associated with lower extremity atherosclerotic disease in Chinese female diabetic patients,” Cardiovascular Diabetology, vol. 14, no. 1, p. 32, 2015.

[16] P. J. Touboul, “Intima-media thickness of carotid arteries,” Frontiers of Neurology and Neuroscience, vol. 36, pp. 31–39, 2015.

[17] M. F. Li, C. C. Zhao, T. T. Li et al., “The coexistence of carotid and lower extremity atherosclerosis further increases cardiovascular risk in type 2 diabetes,” Cardiovascular Diabetology, vol. 15, no. 1, p. 43, 2016.

[18] C. R. L. Cardoso, N. C. Leite, C. B. M. Moram, and G. F. Salles, “Long-term visit-to-visit glycemic variability as predictor of micro- and macrovascular complications in patients with type 2 diabetes: the Rio de Janeiro type 2 diabetes cohort study,” Cardiovascular Diabetology, vol. 17, no. 1, p. 33, 2018.

[19] C. Danese, A. R. Vestri, V. D’Alfonso et al., “Do hypertension and diabetes mellitus influence the site of atherosclerotic plaques?,” La Clinica Terapeutica, vol. 157, no. 1, pp. 9–13, 2006.

[20] U. Rajala, M. Laaks, M. Paivansalo, I. Suramo, and S. Keinanen-Kiukaanniemi, “Blood pressure and atherosclerotic plaques in carotid, aortic and femoral arteries in elderly Finns with diabetes mellitus or impaired glucose tolerance,” Journal of Human Hypertension, vol. 19, no. 1, pp. 85–91, 2005.

[21] C. W. Hicks and E. Selvin, “Epidemiology of peripheral neuropathy and lower extremity disease in diabetes,” Current Diabetes Reports, vol. 19, no. 10, p. 86, 2019.

[22] S. Sen, A. Barsun, K. Romanowski, T. Palmieri, and D. Greenhalgh, “Neuropathy may be an independent risk factor for amputation after lower-extremity burn in adults with diabetes,” Clinical Diabetes, vol. 37, no. 4, pp. 352–356, 2019.

[23] S. L. Yang, Y. L. Zhu, R. Han, L. L. Sun, J. X. Li, and J. T. Dou, “Pathophysiology of peripheral arterial disease in diabetes mellitus,” Journal of Diabetes, vol. 9, no. 2, pp. 133–140, 2017.

[24] M. Takahara, O. Iida, S. Kohsaka et al., “Diabetes mellitus and other cardiovascular risk factors in lower-extremity peripheral artery disease versus coronary artery disease: an analysis of 1,121,359 cases from the nationwide databases,” Cardiovascular Diabetology, vol. 18, no. 1, p. 155, 2019.

[25] H. Graz, V. K. D’Souza, D. E. C. Alderson, and M. Graz, “Diabetes-related amputations create considerable public health burden in the UK,” Diabetes Research and Clinical Practice, vol. 135, pp. 158–165, 2018.

[26] G. K. Hansson and P. Libby, “The immune response in atherosclerosis: a double-edged sword,” Nature Reviews. Immunology, vol. 6, no. 7, pp. 508–519, 2006.

[27] Y. Sato, R. Watanabe, N. Uchiyama et al., “Inhibitory effects of vasostatin-1 against atherogenesis,” Clinical Science, vol. 132, no. 23, pp. 2493–2507, 2018.

[28] V. Clerin, H. H. Shih, N. Deng et al., “Expression of the cysteine protease legumain in vascular lesions and functional implications in atherogenesis,” Atherosclerosis, vol. 201, no. 1, pp. 53–66, 2008.

[29] N. Ozawa, Y. Sato, Y. Mori et al., “Legumain promotes athero- sclerotic vascular remodeling,” International Journal of Molecular Sciences, vol. 20, no. 9, p. 2195, 2019.

[30] M. Papaspyridonos, A. Smith, K. G. Burnand et al., “Novel candidate genes in unstable areas of human atherosclerotic plaques,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 26, no. 8, pp. 1837–1844, 2006.

[31] N. N. Lunde, I. Gregersen, T. Ueland et al., “Legumain is upregulated in acute cardiovascular events and associated with improved outcome - potentially related to anti-inflammatory effects on macrophages,” Atherosclerosis, vol. 296, pp. 74–82, 2020.

[32] H. Wu and C. M. Ballantyne, “Metabolic inflammation and insulin resistance in obesity,” Circulation Research, vol. 126, no. 11, pp. 1549–1564, 2020.

[33] F. Schneider, P. J. Saulnier, E. Gand et al., “Influence of micro- and macro-vascular disease and tumor necrosis factor receptor 1 on the level of lower-extremity amputation in patients with type 2 diabetes,” Cardiovascular Diabetology, vol. 17, no. 1, p. 81, 2018.

[34] T. C. Umei, Y. Kishimoto, M. Aoyama et al., “High plasma levels of legumain in patients with complex coronary lesions,” Journal of Atherosclerosis and Thrombosis, vol. 27, no. 7, pp. 711–717, 2020.

[35] I. Gregersen, A. E. Michelsen, N. N. Lunde et al., “Legumain in acute coronary syndromes: a substudy of the PLATO (Platelet Inhibition and Patient Outcomes) trial,” Journal of the American Heart Association, vol. 9, no. 17, article e016360, 2020.

[36] H. Yang, Y. He, P. Zou et al., “Legumain is a predictor of all-cause mortality and potential therapeutic target in acute myocardial infarction,” Cell Death & Disease, vol. 11, no. 11, p. 1014, 2020.